• News

Dr. C. Warren Olanow “Synagile Announces Positive Results from Phase 2a Trial of Continuous Intraoral LD-CD Therapy”

  • News Medical
  • New York, NY
  • (October 08, 2015)

Positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD) were released today. "Motor complications, and specifically OFF time, can have a profoundly negative impact on the lives of Parkinson's disease patients," said Warren Olanow, MD, FRCPC, co-principal investigator of the study and chairman emeritus of the department of neurology at the Icahn School of Medicine at Mount Sinai. “A safe, convenient, noninvasive, nonsurgical, oral levodopa therapy would be a major advance in treatment.” Learn more